Skip to main
  1. Stocks
  2. CytomX Therapeutics
  3. Forecast
CTMX

CytomX Therapeutics (CTMX) Stock Forecast & Price Target

CytomX Therapeutics (CTMX) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CytomX Therapeutics is attractive because its Probody platform targets clinically validated cancer pathways while reducing off-tumor toxicity, a key differentiator in oncology where safety often limits efficacy. Lead asset varseta-m has shown encouraging dose-response in heavily pretreated mCRC, with ORRs of 20% and 32%, disease control rates of 90% and 86%, and mPFS of 6.8 and 7.1 months, while optimized prophylaxis has reduced grade 3 diarrhea to 10%. Its balance sheet also supports execution, with $330M in cash at 2Q26 and runway into at least 2H28, giving it time to advance registrational planning and multiple 1H27 catalysts across CRC, bevacizumab combinations, and CX-801.

Bears say

CytomX Therapeutics is exposed to substantial fundamental risk because its outlook depends heavily on clinical data for BMS-986288 and CX-2051, both of which may fail to show differentiated or acceptable efficacy and safety. The company’s clinical-stage, oncology-focused model leaves it vulnerable to binary trial outcomes, regulatory setbacks, and the possibility that even approved programs may not meet revenue estimates. In addition, both candidates could face commercial pressure from current and future therapies, underscoring a limited margin for error and a challenging path to durable value creation.

CytomX Therapeutics (CTMX) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CytomX Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

CytomX Therapeutics (CTMX) Analyst Forecast & Price Prediction

Get the latest CytomX Therapeutics (CTMX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CytomX Therapeutics (CTMX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CytomX Therapeutics (CTMX) Forecast

Analysts have given CytomX Therapeutics (CTMX) a Buy based on their latest research and market trends.

According to 8 analysts, CytomX Therapeutics (CTMX) has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CytomX Therapeutics (CTMX)


CytomX Therapeutics (CTMX) Analyst Forecast & Price Prediction

Get the latest CytomX Therapeutics (CTMX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CytomX Therapeutics (CTMX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CTMX stock data and trends